failed trials

Lung
Biotech

ArriVent’s phase 3 lung cancer trial flops, sinking stock

A phase 3 lung cancer study of ArriVent BioPharma’s EGFR inhibitor has missed its primary endpoint, sending the biotech’s stock down 57%.
Nick Paul Taylor Oct 6, 2026 10:51am
Dont cross signal on city street

Foghorn lays off 40% of employees as Lilly collab collapses

Oct 1, 2026 8:36am
Make a delay and accumulation of outstanding tasks Full stop

Roche drops obesity antibody after flunked interim analysis

Sep 28, 2026 11:03am
positive negative up down good bad mixed

Acadia misses mark in Alzheimer’s but continues phase 3 program

Sep 24, 2026 9:46am
Make a delay and accumulation of outstanding tasks Full stop

Immunovant ends cutaneous lupus program after phase 2 flop

Sep 23, 2026 8:59am
Podcast
Blue background with repeated three-dimensional dollar-sign shapes and the words The Top Line in red and white at the b

Inside the growing world of biopharma prediction markets

Sep 18, 2026 9:39am